Detail akcie Puma online

Business Summary: Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Puma Biotechnology Inc revenues increased 3% to $235.6M. Net income increased from $2K to $21.6M. Revenues reflect Royalty revenue increase of 16% to $32.5M, Product Revenue, net increase of 2% to $203.1M. Net income benefited from Legal verdict expense decrease from $12.5M (expense) to $0K, Professional fees and expenses decrease of 11% to $34M (expense).